Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma-Reference-Cited by-全球学者库

Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma

Published:2022-11-15 Issue:0 Volume:0 Page:
ISSN:2224-4018
Container-title:Journal of Translational Internal Medicine
language:en
Short-container-title:

Author:

Shen Xuqing¹,Niu Ningning¹,Xue Jing¹

Affiliation:

1. State Key Laboratory of Oncogenes and Related Genes, Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Cancer Institute, Shanghai Jiao Tong University , Shanghai 200127 , China

Abstract

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an extremely high lethality rate. Oncogenic KRAS activation has been proven to be a key driver of PDAC initiation and progression. There is increasing evidence that PDAC cells undergo extensive metabolic reprogramming to adapt to their extreme energy and biomass demands. Cell-intrinsic factors, such as KRAS mutations, are able to trigger metabolic rewriting. Here, we update recent advances in KRAS-driven metabolic reprogramming and the associated metabolic therapeutic potential in PDAC.

Publisher

Walter de Gruyter GmbH

Subject

Internal Medicine

Link

https://www.degruyter.com/document/doi/10.2478/jtim-2022-0022/pdf

Reference105 articles.

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.

2. Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol 2007;20 Suppl 1:S61-70.

3. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2011;2:216-31.

4. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-95.

5. Niu N, Lu P, Yang Y, He R, Zhang L, Shi J, et al. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut 2020;69:715-26.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review);Oncology Reports;2023-10-04

2. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail;World Journal of Clinical Oncology;2023-08-24